Hólyagrák: vizsgálatok itt: Dél-Korea
35 trials · From ClinicalTrials.gov, checked 2026. november 10.. Ask the study team whether a trial fits you.
- No phaseTaking peopleA Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy in Korea
- Where
- Suwon
- Életkor
- 18 év and over
- People
- 1
- Run by
- Janssen Korea, Ltd., Korea
See details and how to joinNCT07735793 - 1/2. fázisTaking peopleStudy of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Where
- Busan, Cheongju-si, Gyeonggi-do, Hwasun, Incheon, Seongnam-si, Seoul, Suwon
- Életkor
- 18 év and over
- People
- 340 worldwide
- Run by
- Inhibrx Biosciences, Inc
See details and how to joinNCT04198766 - 1. fázisTaking peopleA Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 294 worldwide
- Run by
- Pfizer
See details and how to joinNCT07206225 · EU 2025-521756-39-00 - 1. fázisTaking peopleFORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 677 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05614739 · EU 2022-502755-59-00 - 1. fázisTaking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - 2. fázisTaking peopleA Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Where
- Gangnam-Gu, Guro-gu, Hwasun-Eup, Jongno-gu, Seodaemun-gu, Seoul, Suwon
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT06695845 · EU 2024-516551-41-00 - 2. fázisTaking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Jongno -Gu, Seoul
- Életkor
- 18 év and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - 3. fázisTaking peopleA Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
- Where
- Chuncheon, Gyeongin, Sangam-dong, Seoul
- Életkor
- 18 év and over
- People
- 641 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06319820 - 3. fázisTaking peopleA Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
- Where
- Cheongju-si, Ganggu, Seongnam, Seoul
- Életkor
- 18 év and over
- People
- 220 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06919965 · EU 2024-519493-39-00 - 2. fázisTaking peopleA Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
- Where
- Gyeonggi-do, Hwasun, Seongnam-si, Seoul
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07475806 - 3. fázisTaking peopleTrial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
- Where
- Goyang-si, Hwasun, Seoul, Yangsan
- Életkor
- 18 év and over
- People
- 454 worldwide
- Run by
- Ferring Pharmaceuticals
See details and how to joinNCT06510374 · EU 2024-512029-10-00 - 3. fázisTaking peopleA Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
- Where
- Hwasun, Seoul, Yangsan
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Ferring Pharmaceuticals
See details and how to joinNCT06545955 · EU 2024-512177-27-01 - 3. fázisTaking peopleEnfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
- Where
- Daegu, Seongnam-si, Seoul
- Életkor
- 18 év and over
- People
- 390 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07566156 · EU 2026-525612-34-00 - 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Daegu, Gyeonggi-do, Seongnam, Seoul
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - No phaseTaking peopleA Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
- Where
- Busan, Daegu, Daejeon, Goyang-si, Incheon, Jeollanam-do, Jeonju, Seoul, Suwon
- People
- 228
- Run by
- Astellas Pharma Korea, Inc.
See details and how to joinNCT06011954 - 1/2. fázisTaking peopleGI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
- Where
- Daejeon, Seoul, Suwon
- Életkor
- 18 év and over
- People
- 317 worldwide
- Run by
- GI Innovation, Inc.
See details and how to joinNCT04977453 - 3. fázisTaking peopleA Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Where
- Goyang-si, Junggu, Namdong-gu, Seongnam, Seoul
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07218380 · EU 2025-522855-25-00 - 1/2. fázisTaking peopleKEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 55 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07232602 · EU 2025-522253-19-00 - 1/2. fázisTaking peopleA Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 48 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05562830 · EU 2023-506384-34-00 - 1. fázisTaking peopleA Phase 1/1b Study of IAM1363 in HER2 Cancers
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 383 worldwide
- Run by
- Iambic Therapeutics, Inc
See details and how to joinNCT06253871 - 1. fázisTaking peopleFirst-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 150 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06644755 - 1/2. fázisTaking peopleA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Where
- Daegu, Goyang-si, Incheon, Seoul
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00 - 1/2. fázisTaking peopleLEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- Where
- Hwasun, Seongnam, Seoul
- Életkor
- 18 év and over
- People
- 350 worldwide
- Run by
- enGene, Inc.
See details and how to joinNCT04752722 · EU 2024-512900-20-00 - 2. fázisTaking peopleA Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Where
- Hwasun, Pusan, Seoul, Suwon
- Életkor
- 8 év and over
- People
- 254 worldwide
- Run by
- Fore Biotherapeutics
See details and how to joinNCT05503797 · EU 2024-513578-23-00 - 3. fázisTaking peopleAn Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 915 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07720284